Skip to main content

Orchid s Revenues Gain 5.3 Percent in Q2 as Loss Narrows

NEW YORK, July 28 (GenomeWeb News) - Orchid Cellmark today reported increased revenues and narrowed losses for the second quarter of 2005.

 

The company had $15.8 million in revenues, up 5.3 percent from $15 million for the second quarter of 2004.

 

Research and development costs stayed flat, at $417,000, compared to $454,000 during last year's second quarter.

 

Orchid's net loss totaled $1.8 million, or $.07 per share, down from $2.1 million, or $.10 per share, for the year-ago period.

 

As of June 30, Orchid had $12.7 million in cash and cash equivalents, and $14.7 million in short-term investments.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.